Firstly, having access to the right data or have a means to generate that data.
Secondly, not validating tools correctly that enables trust, and subsequent scale-up.
Finally, general cultural hinderence to adopting new tools or not having defined processes to counteract the issue.

The design of new molecules and generating new hypotheses for further testing.

The identification of new targets, the design/optimization of new molecules, patient segmentation and clinical trail recruitment

The ability to search across knowledge base in the company for ideas and questions rather than just text-to-text matches